IVM

Infectious Disease Specialist Calls Campaign against Repurposed Drugs in COVID-19 a ‘Great Hypocrisy’

Retrieved on: 
Thursday, March 21, 2024
Vanderbilt University, COVID, HCQ, Rheumatoid arthritis, Infection, Azithromycin, Lupus, Diabetes, COVID-19, Patient, Knowledge, Journal, Mortality, Addiction, Hydroxychloroquine, AAPS, Dysautonomia, Physician, Ivermectin, IVM, Pharmaceutical industry

Just before the death-knell announcement, Dr. Hoffman notes, substantial evidence favoring early use of HCQ had been submitted for publication by Dr. Harvey Risch of Yale.

Key Points: 
  • Just before the death-knell announcement, Dr. Hoffman notes, substantial evidence favoring early use of HCQ had been submitted for publication by Dr. Harvey Risch of Yale.
  • “In fact, all evidence is inherently flawed.”
    Dr. Hoffman points out how inconsistencies and double standards reveal the FDA’s hypocrisy regarding HCQ and ivermectin (IVM).
  • Paxlovid, he writes, has not been shown to be effective in hospitalized COVID patients, whereas the “flawed” study of HCQ demonstrated a greater than 60 percent benefit in reducing mortality.
  • “There is in fact a corpus of knowledge about the use of HCQ, IVM, and other off-label drugs, for example, at c19hcq.org, c19IVM.org18, and earlycovidcare.org,” Dr. Hoffman states.

Gameto Announces Patient Experience Data Demonstrating Investigational In Vitro Maturation Solution Well Tolerated with Higher Patient Satisfaction Rates than Conventional Fertility Stimulation

Retrieved on: 
Tuesday, April 2, 2024
Disease, Biotechnology, Data analysis, Abdominal pain, Patient, IVF, COS, Female, Fertility, Manuscript, Fertilisation, Freezing, Woman, OHSS, Pain, Vomiting, IPSC, FDA, IVM, Ovarian hyperstimulation syndrome, Cell, Birth control

NEW YORK, April 2, 2024 /PRNewswire/ -- Gameto, a female-led biotechnology company with a mission to redefine women's healthcare, today announced encouraging new findings from a study evaluating how minimal controlled ovarian stimulation (COS) in combination with Fertilo, their novel investigational in vitro maturation (IVM) solution containing engineered ovarian support cells (OSC-IVM) to mature eggs outside of the body, affected patients' egg retrieval experiences when compared to conventional stimulation. The data analysis found that women undergoing minimal hormonal stimulation for OSC-IVM reported experiencing few side effects, lower levels of pain after retrieval, and higher satisfaction levels with the shortened stimulation procedure, compared to conventional stimulation for in vitro fertilization (IVF).

Key Points: 
  • The data analysis found that women undergoing minimal hormonal stimulation for OSC-IVM reported experiencing few side effects, lower levels of pain after retrieval, and higher satisfaction levels with the shortened stimulation procedure, compared to conventional stimulation for in vitro fertilization (IVF).
  • "We are encouraged by these and previously published efficacy data which demonstrate that combining minimal hormonal stimulation with our investigational in vitro maturation solution may help women navigating fertility treatments avoid many of the common side effects associated with the conventional IVF hormone protocol.
  • Gameto's goal in developing Fertilo is to make fertility treatments more convenient, safer, and accessible for a wider patient population.
  • [1],[2] In contrast, the participants in this analysis who underwent minimal ovarian stimulation cycles followed by OSC-IVM yielded no incidence of OHSS.

Gameto Unveils New Data on In Vitro Maturation Product Candidate Fertilo During Four Presentations at the 2023 American Society for Reproductive Medicine

Retrieved on: 
Thursday, October 19, 2023
Gold, Human, Cell engineering, Fertility, RMA, IVM, RNA, Biotechnology, Spindle apparatus, Congress, Research, Society, F1, Reproductive medicine, IVF, Egg, Oocyte, Cell, Partnership, Behavior informatics, Abstract, American Society for Reproductive Medicine, ASRM, Woman, Safety, Patient, Gene expression, Mineral oil

Gameto's findings show their product candidate, Fertilo, is able to improve egg maturation and embryo development in shortened human minimal stimulation cycles.

Key Points: 
  • Gameto's findings show their product candidate, Fertilo, is able to improve egg maturation and embryo development in shortened human minimal stimulation cycles.
  • The combined findings are an important evidence package as a next step in advancing this reproductive technology.
  • NEW YORK, Oct. 19, 2023 /PRNewswire/ -- Gameto, a female-led biotechnology company with a mission to redefine women's healthcare, presented four abstracts at the 2023 American Society for Reproductive Medicine (ASRM) Congress.
  • The findings show that Fertilo not only matures more eggs, but results in better gene expression and genetic health quality than traditional IVM.

Ball Aerospace Completes Testing on Space Systems Command Operational Weather Monitoring Satellite

Retrieved on: 
Thursday, September 7, 2023
Constellation, Energy, MWI, Telephone numbers in Hungary, ECP, Constellation Observing System for Meteorology, Ionosphere, and Climate, Meteorology, IVM, Vandenberg Space Force Base, Intelligence, Weather System Follow-on Microwave, Joint Polar Satellite System, Ball, OMPS, Weather, Strategic Operations, Space Systems Command, Ozone, Communications satellite, Ball Aerospace & Technologies

BROOMFIELD, Colo., Sept. 7, 2023 /PRNewswire/ -- Ball Aerospace successfully concluded testing on the Weather System Follow-on – Microwave (WSF-M) satellite this week, representing the completion of the first of two satellites Ball is delivering for the U.S. Space Force's Space Systems Command next-generation operational environmental satellite system.

Key Points: 
  • BROOMFIELD, Colo., Sept. 7, 2023 /PRNewswire/ -- Ball Aerospace successfully concluded testing on the Weather System Follow-on – Microwave (WSF-M) satellite this week, representing the completion of the first of two satellites Ball is delivering for the U.S. Space Force's Space Systems Command next-generation operational environmental satellite system.
  • "The completion of the WSF-M satellite is an important milestone in Ball Aerospace's ongoing mission to protect what matters most," said Hope Damphousse, vice president, Strategic Operations, Ball Aerospace.
  • The satellite will also host a government-built Energetic Charged Particle (ECP) sensor that will provide space weather measurements in low-Earth orbit.
  • Last year, Ball Aerospace was awarded a follow-on contract to build and deliver a second WSF-M satellite, which is expected to be completed in early 2026.

Mountain Valley MD Provides Business Update

Retrieved on: 
Thursday, August 10, 2023
Health, Clinical Trials, General Health, Research, Science, Biotechnology, GMP, Communication, Fertilizer, Refrigeration, IVM, Temperature, Solubility, OF, Logic, Transport, Environment, Toxicity, Consultant, Biomass, Population growth, Photosynthesis, Eurasian carp, CSE, Overalls, AC, OMRI, FRA, Government, Climate change, Animal, Water, Contract research organization, Mortality, Drug, Lead, Agriculture, Calendar, Nutrient, Eon, Sale, Republic, Licensee, Fishery, Video game, Property management, Pharmaceutical industry, Ivermectin, Charaxes agrarius, Tilapia, Circadian rhythm, LATAM

Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP) is pleased to provide a business update and details of its current progress.

Key Points: 
  • Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP) is pleased to provide a business update and details of its current progress.
  • “The MVMD team and our extensive network of partners has been making significant progress on our commercialization objectives,” stated Dennis Hancock, President & CEO of Mountain Valley MD.
  • MVMD is currently conducting business development activity in Mexico, Central America, South America, and the United States of America.
  • The initial business development and Agrarius product registration processes are focused on Colombia, Brazil, Uruguay, Panama and Mexico.

Mountain Valley MD Announces Publication of Soluvec™ Trial Data in Therapeutic Delivery

Retrieved on: 
Thursday, August 10, 2023
Health, Clinical Trials, General Health, Research, Science, Biotechnology, Drug, Human, CSE, Hancock, Pharmacovigilance, Pharmacokinetics, Avermectin, IVM, Livestock, FRA, Solubility, Drug resistance, Republic, Pesticide, Animal, Dog, Water, Knowledge, Key finding attacks, Safety, Ivermectin, Pharmaceutical industry

Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP), a leading-edge publicly traded biotech company whose science includes that of novel solubilization methods for therapeutic compounds, is pleased to announce the recent peer-reviewed publication of the Company’s Soluvec™ study data in the journal, Therapeutic Delivery.

Key Points: 
  • Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP), a leading-edge publicly traded biotech company whose science includes that of novel solubilization methods for therapeutic compounds, is pleased to announce the recent peer-reviewed publication of the Company’s Soluvec™ study data in the journal, Therapeutic Delivery.
  • The published study highlights the benefits of the Company’s patented Soluvec™ formulation, a novel, solvent-free aqueous Ivermectin invention.
  • The study confirmed that parenteral administration of Soluvec™ led to an Ivermectin drug exposure approximately seven times higher than traditional oral drug dosing, with greater bioavailability, offering potential for enhanced therapeutic effectiveness.
  • Key Findings from the Study:
    Improved Solubility with Soluvec™: In the resolubilized product, Soluvec™, Ivermectin was present as a mix of 28.0 nm particles and polysorbate-solubilized free Ivermectin.

ESMA finds adequate setup of measures to reduce volatility in trading of energy derivatives

Retrieved on: 
Saturday, July 1, 2023
European Securities and Markets Authority, II, Council Implementing Regulation (EU) No. 282/2011, ESMA, Union, Markets in Financial Instruments Directive 2014, IVM, IVMS, Council, Regulation, Calibration, Cryptocurrency, EU

ESMA finds adequate setup of measures to reduce volatility in trading of energy derivatives

Key Points: 
  • ESMA finds adequate setup of measures to reduce volatility in trading of energy derivatives
    The European Securities and Markets Authority (ESMA), the EU’s financial markets regulator and supervisor, has today published its Report on the implementation and functioning of the Intra-day Volatility Management Mechanism (IVM).
  • The IVM aims at limiting extreme volatility of prices in energy derivatives markets within one day.
  • ESMA finds them adequately calibrated, with the caveat of the assessment having been done in a period with no evidence of protracted volatility episodes affecting energy commodity derivatives trading.
  • ESMA will continue requesting updates on the implemented IVMs from trading venues on a quarterly basis as per the Regulation and monitoring developments in the trading of energy commodity derivatives.

Stork Club Reproductive Benefits Solution adds Neway Fertility and Utah Fertility Center to its National Fertility Centers of Excellence Network

Retrieved on: 
Tuesday, June 27, 2023
Newai, Male, Stork Club, Partnership, Patient satisfaction, MS, Patient, Physician, SAN, Fertility, Health, TMRW, Female, Nightclub, Birth control, IVM, MD

SAN FRANCISCO, June 27, 2023 /PRNewswire/ -- Stork Club, a pioneering family-building benefits solution, today announced its partnership with high-performance fertility clinics Neway Fertility and Utah Fertility Center. The partnership gives Stork Club members access to best-in-class care at Neway's clinic on the Upper West Side of Manhattan and five Utah Fertility Center clinics in Utah and Idaho.

Key Points: 
  • SAN FRANCISCO, June 27, 2023 /PRNewswire/ -- Stork Club , a pioneering family-building benefits solution, today announced its partnership with high-performance fertility clinics Neway Fertility and Utah Fertility Center .
  • The partnership gives Stork Club members access to best-in-class care at Neway's clinic on the Upper West Side of Manhattan and five Utah Fertility Center clinics in Utah and Idaho.
  • Both Neway Fertility and Utah Fertility Center have extensive expertise working with diverse patients and offer comprehensive diagnostics and cutting-edge individualized fertility treatments.
  • Through our partnership with Stork Club, we're extending our access to industry-leading fertility care," said Shawn E. Gurtcheff, MD, MS and medical director at Utah Fertility Center.

Ball Aerospace Enters Final Stages of Building Space Force's Next-Gen Operational Weather Satellite

Retrieved on: 
Tuesday, January 10, 2023
Constellation, SBEM, Ozone, Brodmann area, Strategic Operations, Energy, Special sensor microwave/imager, United States Space Force, Weather System Follow-on Microwave, NOAA, Defense, Joint Polar Satellite System, ECP, Meteorology, MWI, Starcom: The U.S. Space Force, United States Department of Defense aerospace vehicle designation, NASA, United States Department of Defense, Environmental monitoring, JPSS-3, WSF, IVM, United, Ball Aerospace & Technologies, University Corporation for Atmospheric Research, Suomi NPP, Weather, National Space Organization, Heart, OMPS, Snow, Atmosphere, LEO, Intelligence, Communications satellite

BROOMFIELD, Colo., Jan. 10, 2023 /PRNewswire/ -- Ball Aerospace completed the spacecraft bus for the Weather System Follow-on-Microwave (WSF-M) satellite, the U.S. Space Force's next-generation operational environmental satellite system.

Key Points: 
  • BROOMFIELD, Colo., Jan. 10, 2023 /PRNewswire/ -- Ball Aerospace completed the spacecraft bus for the Weather System Follow-on-Microwave (WSF-M) satellite, the U.S. Space Force's next-generation operational environmental satellite system.
  • Ball also finalized environmental testing on the Microwave Imager (MWI) instrument and has started final space vehicle assembly, integration and testing.
  • Ball Aerospace was recently awarded the contract modification to develop and build the second WSF-M space vehicle, expected to be completed by late 2027.
  • Ball Aerospace has played key roles on numerous operational weather satellite programs.

CENTEGIX Launches Strategic Partnership with Leading K-12 Visitor Management Solution, Ident-A-Kid

Retrieved on: 
Tuesday, November 15, 2022
K–12, Technology, Work, IVM, Student, Partnership, Safety, School, Culture, Learning, CEO, Wi-Fi, Child, SRO, Solution, Toy, Medicine, Management

ATLANTA, Nov. 15, 2022 /PRNewswire/ -- CENTEGIX, the leader in incident response solutions, announced a strategic partnership with Ident-A-Kid, a leading provider of K-12 school and child safety solutions, that will extend the ability of schools to maintain a safe and secure environment for students, staff, and visitors through Ident-A-Kid's award winning solution called iVisitor Management™ (IVM).

Key Points: 
  • This partnership will bring together innovative technologies integral to fostering a culture of safety where the focus is on learning.
  • Customers of CENTEGIX will now have access to IVM, which is currently utilized across the country in over 7,000 schools.
  • "The strong alignment between our CrisisAlert technology and Ident-A-Kid's iVisitor Management makes this partnership an ideal fit for our companies.
  • Based in St. Petersburg, FL, Ident-A-Kid is a leading provider of K-12 school and child safety solutions, including visitor management (iVisitor Management).